Hoffmann, G.V.* ; Gottschlich, A.* ; Subklewe, M.* ; Kobold, S.
Novel approaches to CAR T cell target identification in acute myeloid leukemia.
Curr. Opin. Pharmacol. 82:102524 (2025)
Identifying safe and effective CAR T cell targets in acute myeloid leukemia (AML) is challenging due to the disease's complexity and overlap with normal hematopoiesis. This review highlights advances in target discovery for AML, emphasizing innovative approaches. Structural surfaceomics identifies tumor-specific protein conformations, while AI-driven single-cell RNA sequencing integrates multi-source data to pinpoint optimal targets. Refined cell surface capture technology maps the AML surfaceome without relying on predefined antibodies. These strategies enhance CAR T cell specificity and minimize off-tumor effects, offering promising pathways for safer and more effective AML treatments and broader cancer therapies.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Stem-cells; Antibody; Therapy; Heterogeneity; Expression; Ozogamicin; Cultures; Cancer
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2025
Prepublished im Jahr
0
HGF-Berichtsjahr
2025
ISSN (print) / ISBN
1471-4892
e-ISSN
1471-4973
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 82,
Heft: ,
Seiten: ,
Artikelnummer: 102524
Supplement: ,
Reihe
Verlag
Elsevier
Verlagsort
London
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
Institut(e)
Unit for Clinical Pharmacology (KKG-EKLiP)
POF Topic(s)
30203 - Molecular Targets and Therapies
Forschungsfeld(er)
Immune Response and Infection
PSP-Element(e)
G-522100-001
Förderungen
Bavarian Research Foundation (BAYCELLATOR)
Marie Sklodowska-Curie Training Network for Optimizing Adoptive T Cell Therapy of Cancer - Horizon 2020 programme of the European Union
German Cancer Aid
Wilhelm-Sander-Stiftung
Ernst Jung Stiftung
Institutional Strategy LMUexcellent of LMU Munich
Bavarian Ministry for Economical Affairs
Bundesministerium fur Bildung und Forschung
European Research Council
Deutsche Forschungsgemeinschaft (DFG)
Fritz-Bender Foundation
Monika-Kutzner Foundation for Cancer Research
Horizon 2020 programme of the European Union
Copyright
Erfassungsdatum
2025-05-11